From Underperformance To Opportunity: Biotech's Case For 2025
Source: SeekingAlpha
2025-01-29 06:30:00 ET
Summary
- Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking innovations like mRNA cancer vaccines and CRISPR-based therapies.
- Structural shifts, including operational discipline and AI-powered drug discovery, signal resilience and a long-term growth narrative for biotech, even amidst macroeconomic and regulatory challenges.
- Historically low valuations, coupled with sector rotation dynamics and favorable policy initiatives, position biotech as a compelling opportunity for investors seeking growth in 2025.
By Christopher Gannatti, CFA ...
Read the full article on Seeking Alpha
For further details see:
From Underperformance To Opportunity: Biotech's Case For 2025
Global X Telemedicine & Digital Health ETF
NASDAQ: EDOC
EDOC Trading
1.27% G/L:
$9.45 Last:
9,067 Volume:
$9.3299 Open:
